| adults |
cohort |
68 |
29 |
20–30 years old, adult, adult cohort, adult humans, adult participants, adult patients, adult populations, adult rats, adult samples, adult subjects, adulthood, adults, human adults, middle adulthood, middle-aged, older and younger adults |
| adult sample |
cohort |
6 |
2 |
adult, adult samples |
| adventurousness |
phenotype |
2 |
1 |
adventurousness, self-reported tendency to be adventurous vs. cautious |
| adverse childhood experiences |
phenotype |
20 |
11 |
ACE, ACEs, CAs, educational or home-life disruptions during childhood, familial economic difficulties, family adversity scores, history of childhood adversity, home violence |
| adverse effects |
phenotype |
5 |
3 |
harmful side effects, unwanted adverse effects |
| adverse physical health outcomes |
phenotype |
2 |
1 |
adverse physical health outcomes |
| AEA |
drug |
2 |
2 |
Anandamide, anandamide, arachidonylethanolamine |
| Affect dysregulation |
phenotype |
2 |
1 |
affect dysregulation |
| affected |
phenotype |
3 |
— |
diseased individuals |
| affected individuals |
cohort |
5 |
3 |
affected, affected cohort, affected females, affected individuals from trio data, cases |
| affected offspring |
phenotype |
2 |
1 |
|
| affected status |
phenotype |
3 |
— |
|
| affective disorders |
phenotype |
15 |
8 |
AFF, affective disorder, affective disorders, mood disorders |
| affective symptoms |
phenotype |
3 |
1 |
mood symptoms, number of affective symptoms, unpleasant affective symptoms |
| affect regulation |
phenotype |
2 |
2 |
|
| affiliation with deviant peers |
phenotype |
2 |
1 |
deviant peer affiliation, deviant peers affiliation, peer deviancy |
| Affiliative behavior |
phenotype |
3 |
2 |
|
| Affymetrix |
drug |
10 |
7 |
Affymetrix, Affymetrix arrays |
| Affymetrix 5.0 |
drug |
2 |
1 |
Affymetrix 5.0 genotyping platform |
| Affymetrix 6.0 |
drug |
6 |
2 |
Affy 6.0, Affymetrix 6.0 genotyping |
